CINCINNATI, March 8 Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced several of its executives will present on key industry issues at the Drug Information Association (DIA) 22nd Annual EuroMeeting March 8-10, 2010, in Monaco, as well as at the Cambridge Healthtech Institute's Summit for Clinical Ops Executives (SCOPE) Conference, also March 8-10 in Philadelphia. Kendle experts will address key topics in clinical development including adaptive trial design, interim analysis, electronic adjudication and clinical research in Latin America.
Kendle Speakers at DIA EuroMeeting
Dr. Sietsema is a global thought leader on clinical development planning. He is an accomplished author - the most recent of his four books is Preparation and Maintenance of the IND Application in eCTD Format - as well as speaker and has presented at more than 50 professional conferences around the world. In 2007 he was named one of the "Notable People in R&D" by industry publication R&D Directions.
Dr. Sennewald is an expert in biostatistical analysis and process improvement with a strong scientific and regulatory background. She has spoken at conferences worldwide and has contributed to numerous industry and academic publications.
Kendle Speakers at SCOPE
Dr. Kilpatrick is an expert on clinical development safety and pharmacovigilance as well as process improvement. He recently spearheaded the development of Kendle's proprietary TrialEAS(TM) software, a Web-based solution that enables independent adjudication of clinical endpoints and assists investigators in selecting appropriate patients for enrollment into clinical studies. In recognition of this work, he was named one of the "Notable People in R&D" for 2010 by R&D Directions.
Dr. Hurley is one of the preeminent experts on clinical development in Latin America. He has more than three decades of experience in the region and has spoken around the world on the benefits and nuances of conducting trials in Latin America.
Visit with Kendle's experts before or after their presentations to discuss the Company's best-in-class delivery of Phase I-IV clinical development programs that increase efficiency and value for its customers.
Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.
Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.
Tuesday, March 9, 4 p.m. - Session 0105 Recent Advances in Adaptive Clinical Trial Design William K. Sietsema, PhD Vice President, Regulatory Consulting and Submissions
SOURCE Kendle International Inc.